| Title |
Strength Testing in Motor Neuron Diseases
|
|---|---|
| Published in |
Neurotherapeutics, January 2017
|
| DOI | 10.1007/s13311-016-0472-0 |
| Pubmed ID | |
| Authors |
Jeremy M Shefner |
| Abstract |
Loss of muscle strength is a cardinal feature of all motor neuron diseases. Functional loss over time, including respiratory dysfunction, inability to ambulate, loss of ability to perform activities of daily living, and others are due, in large part, to decline in strength. Thus, the accurate measurement of limb muscle strength is essential in therapeutic trials to best understand the impact of therapy on vital function. While qualitative strength measurements show declines over time, the lack of reproducibility and linearity of measurement make qualitative techniques inadequate. A variety of quantitative measures have been developed; all have both positive attributes and limitations. However, with careful training and reliability testing, quantitative measures have proven to be reliable and sensitive indicators of both disease progression and the impact of experimental therapy. Quantitative strength measurements have demonstrated potentially important therapeutic effects in both amyotrophic lateral sclerosis and spinobulbar muscular atrophy, and have been shown feasible in children with spinal muscular atrophy. The spectrum of both qualitative and quantitative strength measurements are reviewed and their utility examined in this review. |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 96 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 16 | 17% |
| Student > Master | 13 | 14% |
| Student > Bachelor | 10 | 10% |
| Researcher | 6 | 6% |
| Student > Doctoral Student | 4 | 4% |
| Other | 15 | 16% |
| Unknown | 32 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 25% |
| Nursing and Health Professions | 11 | 11% |
| Neuroscience | 8 | 8% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Engineering | 5 | 5% |
| Other | 9 | 9% |
| Unknown | 34 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 December 2020.
All research outputs
#8,261,756
of 25,373,627 outputs
Outputs from Neurotherapeutics
#756
of 1,308 outputs
Outputs of similar age
#140,760
of 421,655 outputs
Outputs of similar age from Neurotherapeutics
#17
of 23 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 421,655 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.